Kane Biotech Inc. (KNE.V)
TSXV · CAD · Healthcare · Biotechnology
CA$0.035 (+0.00%) as of
Key statistics
- Market cap
- 7.18M
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0200 – 0.0500
- Beta
- 0.24
- Revenue (TTM)
- 38.72k
- Profit margin
- 0.00%
- Volume
- 10.00k
About Kane Biotech Inc.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate acne vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Winnipeg, MB, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.